Polycomb-mediated silencing in neuroendocrine prostate cancer

BACKGROUND: Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer (PCa) for which the median survival remains less than a year. Current treatments are only palliative in nature, and the lack of suitable pre-clinical models has hampered previous efforts to develop no...

Descripción completa

Detalles Bibliográficos
Autores principales: Clermont, Pier-Luc, Lin, Dong, Crea, Francesco, Wu, Rebecca, Xue, Hui, Wang, Yuwei, Thu, Kelsie L, Lam, Wan L, Collins, Colin C, Wang, Yuzhuo, Helgason, Cheryl D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391120/
https://www.ncbi.nlm.nih.gov/pubmed/25859291
http://dx.doi.org/10.1186/s13148-015-0074-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391120/
https://www.ncbi.nlm.nih.gov/pubmed/25859291
http://dx.doi.org/10.1186/s13148-015-0074-4

Ejemplares similares